FGF19 and type 2 diabetes mellitus: In a phase 2 randomized controlled trial in patients with type 2 diabetes, aldafermin (NGM282), an engineered FGF19 analog, did not reduce plasma glucose or HbA1c, although modest weight reduction was observed at higher dose [7].